DOR BioPharma has announced that the European Union's European Agency for the Evaluation of Medicinal Products (EMEA) has granted the company Small and Medium Sized Enterprises (SME) incentives.
Under this program, DOR BioPharma is eligible for assistance and training from EMEA in the pursuit of marketing authorization applications as well as reduced fees related to the applications. The company's announcement stated its primary goal is to obtain European approval for its lead product, orBec (oral beclomethasone dipropionate), which is being developed to treat gastrointestinal Graft-versus-Host disease and other GI conditions involving severe inflammation.
DOR BioPharma specializes in treatments for life-threatening side effects of cancer, cancer treatments, gastrointestinal diseases and biomedical countermeasures.
